SBI-477

SBI-477 is a chemical probe that stimulates insulin signaling by deactivating the transcription factor MondoA. SBI-477 can lead to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) . SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes[1].

Product Specifications

CAS Number

[781628-99-7]

UNSPSC

12352005

Target

Arrestin; Fluorescent Dye; Insulin Receptor; LXR

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/sbi-477.html

Concentration

10mM

Purity

98.0

Solubility

DMSO : 65 mg/mL (ultrasonic)

Smiles

O=C(NC1=NC(C2=CC=C(OC)C=C2)=CS1)C3=CC=C(OCC(N4CCOCC4)=O)C(OC)=C3

Molecular Formula

C24H25N3O6S

Molecular Weight

483.54

References & Citations

[1]Ahn B, et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J Clin Invest. 2016 Sep 1;126 (9) :3567-79.|[2]Nakayama, Y., et al., (2024) . Systemic Deletion of ARRDC4 Improves Cardiac Reserve and Exercise Capacity in Diabetes. Circulation research, 135 (3), 416–433.